Showcases Stock ranks Forex

Biocryst Pharma Inc (BCRX)
14.7  0.09 (0.62%) 10-22 16:00
Open: 14.6 Pre. Close: 14.61
High: 14.77 Low: 14.35
Volume: 1,521,701 Market Cap: 2,627M
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in Phase I clinical trials to treat fibrodysplasia ossificans progressiva; and Galidesivir, a RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Prices Prediction (Update @5:00pm)
If tomorrow: Open lower Open higher
High: 14.789 - 14.849 14.849 - 14.906
Low: 14.202 - 14.268 14.268 - 14.331
Close: 14.594 - 14.698 14.698 - 14.797
Stock Technical Analysis
Target: Six months: 18.31
One year: 21.39
Support: Support1: 14.09
Support2: 13.10
Resistance: Resistance1: 15.68
Resistance2: 18.31
Pivot: 14.49
Moving Averages: MA(5): 14.72
MA(20): 14.49
MA(100): 15.70
MA(250): 11.95
MACD: MACD(12,26): -0.07
Signal(12,26,9): -0.13
%K %D: %K(14,3): 58.10
%D(3): 62.52
RSI: RSI(14): 49.11
52-Week: High: 18.48
Low: 3.57
Change(%): 282.8
Average Vol(K): 3-Month: 267082
10-Days: 213597
Price, MAs and Bollinger Bands
Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.

BCRX has closed below upper band by 41.1%. Bollinger Bands are 8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
Stock chart
Stock News
Fri, 22 Oct 2021
Zacks Investment Research Lowers BioCryst Pharmaceuticals (NASDAQ:BCRX) to Sell - MarketBeat

Thu, 21 Oct 2021
Biocryst (BCRX) gains 1.95% on Moderate Volume October 21 -

Wed, 20 Oct 2021
BioCryst to Report Third Quarter 2021 Financial Results on - GlobeNewswire

Mon, 18 Oct 2021
BioCryst Pharmaceuticals Inc. (BCRX): Keep paying attention to its insider activity - The Fosters Leader

Mon, 11 Oct 2021
BioCryst Pharmaceuticals Inc. (BCRX): What the Financials Tell Us - The Fosters Leader

Thu, 07 Oct 2021
$37.75 Million in Sales Expected for BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) This Quarter - MarketBeat

Financial Analysis
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company's ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Stock Basics & Statistics
Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 177.70
Shares Float (M) 164.02
% Held by Insiders 0.90
% Held by Institutions 59.90
Shares Short (K) 18350
Shares Short Prior Month (K) 19150
Stock Financials
EPS -1.210
Book Value (p.s.) -0.420
Profit Margin -270.53
Operating Margin -229.04
Return on Assets (ttm) -46.0
Return on Equity (ttm)
Qtrly Rev. Growth 1640.1
Gross Profit (p.s.) -0.601
Sales Per Share 0.445
EBITDA (p.s.) -1.016
Qtrly Earnings Growth
Operating Cash Flow (M) -169.32
Levered Free Cash Flow (M) -112.37
Stock Valuation
PE Ratio -12.15
PEG Ratio
Price to Book value -35.00
Price to Sales 33.01
Price to Cash Flow -15.43
Stock Dividends
Dividend Yield
Dividend Growth

Stoxline Lite

Stoxline Pro

Stock Chart

Option Calculator